Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC). Radical nephroureterectomy with an ipsilateral bladder cuff is the ...
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast ...
What Is Transurethral Resection of Bladder Tumor (TURBT)? If you have bladder cancer or suspected bladder cancer, your doctor has probably told you that you need a transurethral resection of the ...
In this phase IIb parallel cohort study, patients with BCG-unresponsive carcinoma in situ (CIS) with/without papillary disease received TAR-200 monotherapy (Cohort 2 [C2]), TAR-200 plus cetrelimab (C1 ...
BCG treatment is the gold-standard therapy for high-grade intermediate-risk and high-risk non-muscle-invasive bladder cancer (NMIBC). However, ~30−40% of patients who receive BCG experience treatment ...
Low-grade non-muscle invasive bladder cancer is a specific category of bladder cancer with a favourable prognosis; however, its management presents several challenges. The risk of stage progression is ...
Bladder cancer is mainly urothelial carcinoma, with non-muscle-invasive and muscle-invasive types, and smoking as a key risk factor. Diagnosis involves cystoscopy, biopsy, urine cytology, and imaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results